A White House spokesperson has officially denied that Donald Trump is the mysterious sole patient who’s been granted access to Eli Lilly’s experimental obesity drug retatruide.
Retatruide is being positioned as the next generation of anti-obesity drugs, with initial data from a Phase 3 trial saying obese patients who took the drug for 80 weeks lost 28% of their starting weight. Hype is building for its release, though it’s currently not authorized for use outside clinical trials.
